Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LifespanningRx vs Vita Bella

LifespanningRx
Graded #324

Lower grade

vs+4.500000000000007
Vita Bella
Graded #238

Higher grade

The verdict

Vita Bella takes it — 64.9/100 to 60.4/100.

Vita Bella grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vita Bella is a Nevada-based telehealth membership platform (Vita Bella Health, LLC) that offers compounded GLP-1 weight-loss medications alongside hormone therapy, peptides, sexual-wellness and anti-aging…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLifespanningRx +1
45
44
Dose & formulationLifespanningRx +1
53
52
Clinical oversightVita Bella +10
81
91
Labs & monitoringVita Bella +24
53
77
FulfillmentEven
83
83
Contract termsLifespanningRx +8
55
47
LifespanningRx · left barVita Bella · right bar

The numbers

MetricLifespanningRxVita Bella
WeighScore60.4/10064.9/100
GradeCC
Scorecard rank#324#238
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosed$159/mo (2.5 mg dose, plus a separate fee, compounded)
CoverageAll 50 states46 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
LifespanningRx

Graded #324 · C

Strengths

  • Compounded GLP-1 (semaglutide/tirzepatide) weight-loss program with licensed clinicians included
  • LegitScript-certified and HIPAA-compliant; works with 503A/503B licensed US pharmacies
  • Longevity and peptide protocols alongside weight loss; free membership, no monthly fee
  • Discreet nationwide shipping with 24/365 support
  • Also a turnkey white-label platform for clinics and wellness brands to launch programs

Where it loses points

  • Exact dosing and pricing are shown only after completing the patient assessment
  • Compounded GLP-1s are not FDA-approved finished products
  • States served are not publicly listed
  • Part B2B/white-label, so the consumer experience can vary by partnered clinic
Vita Bella

Graded #238 · C

Strengths

  • Offers both compounded semaglutide (from $109/mo) and tirzepatide (from $159/mo) at member pricing, with supplies and a B-6 add-in included
  • Genuine LegitScript-certified website (seal #4395819) and a clearly disclosed legal entity, Vita Bella Health, LLC (Nevada)
  • Broad access: care published for 46 states plus Washington, D.C., and HSA cards are accepted
  • Fully remote telehealth with video provider consults and quarterly provider check-ins included in the membership
  • Medications dispensed by US FDA-inspected compounding pharmacies; ondansetron for nausea provided at no extra charge

Where it loses points

  • Advertised $109-$159 medication prices require a separate $129/mo membership plus a one-time $99 consult, pushing true cost to ~$238-288/mo
  • Three-month minimum commitment before it renews month-to-month; no refunds on medications and all sales are final
  • Compounding pharmacy partners are not named anywhere on the site — a transparency gap
  • Compounded semaglutide and tirzepatide are not FDA-approved; only the dispensing pharmacies are described as FDA-inspected
  • Disputes are subject to binding arbitration with a class-action waiver, governed by Nevada law (Las Vegas jurisdiction)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard